2007
Embryo–Placento–Maternal Interaction and Biomarkers: From Diagnosis to Therapy – A Workshop Report
Than N, Paidas M, Mizutani S, Sharma S, Padbury J, Barnea E. Embryo–Placento–Maternal Interaction and Biomarkers: From Diagnosis to Therapy – A Workshop Report. Placenta 2007, 28: s107-s110. PMID: 17382999, PMCID: PMC2574429, DOI: 10.1016/j.placenta.2007.01.017.Peer-Reviewed Original Research
2004
Soluble monocyte cluster domain 163, a new global marker of anti‐inflammatory response, is elevated in the first trimester of pregnancy
Paidas M, Ku D, Davis B, Lockwood C, Arkel Y. Soluble monocyte cluster domain 163, a new global marker of anti‐inflammatory response, is elevated in the first trimester of pregnancy. Journal Of Thrombosis And Haemostasis 2004, 2: 1009-1010. PMID: 15140143, DOI: 10.1111/j.1538-7836.2004.00681.x.Peer-Reviewed Original Research
2002
The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
Arkel Y, Paidas M, Ku D. The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagulation & Fibrinolysis 2002, 13: 199-205. PMID: 11943933, DOI: 10.1097/00001721-200204000-00005.Peer-Reviewed Original ResearchMeSH KeywordsActivated Protein C ResistanceAdolescentAdultAgedAged, 80 and overAntiphospholipid SyndromeAntithrombin IIIAntithrombin III DeficiencyAutoimmune DiseasesBiomarkersEnzyme-Linked Immunosorbent AssayFactor VFemaleFibrinFibrin Fibrinogen Degradation ProductsHumansHyperhomocysteinemiaMaleMiddle AgedPeptide FragmentsPeptide HydrolasesProtein C DeficiencyProtein S DeficiencyProthrombinRiskSolubilityThrombophiliaConceptsCoagulation activation markersActivation markersAssessment of hypercoagulabilityPercentage of patientsProthrombotic disordersVascular eventsConsecutive patientsThrombophilic abnormalitiesThrombotic riskPatientsSoluble fibrin polymersTPP levelsMean levelsMarkersAbnormalitiesFibrin polymersHypercoagulability